Scientific Advisory Board
Protagen’s international scientific advisory board brings together key opinion leaders from both the immuno-oncology and autoimmune disease fields.
In collaboration with its expert panels, Protagen benefits from industry-leading expertise, allowing for the development of precision diagnostic solutions that address the immuno-oncology and autoimmune disease markets’ needs.
Contact us to find out more about how Protagen is helping to drive the discovery of effective therapies for immuno-oncology and autoimmune disease.
Professor Vibeke Strand
Professor Strand is a consultant in clinical research and regulatory affairs for pharmaceutical and biotech companies. She has been a clinical rheumatologist for 35 years in a sub-specialty practice in San Francisco as a clinical investigator, and subsequently as Director of Clinical Research at three pharmaceutical and biotech companies, prior to establishing her consulting practice in 1991. She is a member of the clinical faculty at Stanford University, serving as Adjunct Clinical Professor (Division of Immunology and Rheumatology) since September 2000, Clinical Associate Professor since 1993 and has held positions at the University of California, San Francisco.
Her professional interests include the development and validation of outcome measures, and the clinical development and regulatory strategies leading to the approval of new agents for the treatment of autoimmune diseases, including rheumatoid arthritis, systemic lupus erythematosus, systemic sclerosis, gout and osteoarthritis. She has authored over 300 original publications and reviews, 50 chapters, co-edited several books and multiple proceedings.
Professor Matthias Schneider
Professor Schneider is Head of the Rheumatology Clinic at the Hiller Research Unit at Heinrich-Heine-University, Duesseldorf and Rhein-Ruhr, The Cooperation Multipurpose Arthritis Center. He is qualified within internal medicine, rheumatology, physical therapy and endocrinology and has been working in this field now for more than 30 years. In 1988, he was awarded Venia Legendi for Internal Medicine. His major research interests include systemic connective tissue diseases, patient-reported outcomes and risk stratification for inflammatory rheumatic diseases.
From 2013–2014, he was President of the German Society of Rheumatology, and is still leading the development of new guidelines for the treatment of rheumatic diseases. He represented German rheumatology research in the The European League Against Rheumatism (EULAR) recommendations for various topics in systemic lupus erythematosus (SLE). For more than 20 years he supported the German SLE patient group as a board member and has been a medical advisor of Lupus Europe since 2004.
Protagen’s corporate leadership team combines over 40 years of commercial expertise and experience within the biotechnology industry, with a background spanning immunology, oncology, biomarker discovery and more.
Protagen is dedicated to the development of powerful diagnostic tools that aid successful therapeutic development and facilitate improved treatment strategies in the areas of autoimmune disease and immuno-oncology.
Protagen has a number of established and committed investors, but is always looking at entering into new partnerships to help progress its research and commercialization efforts. If you are interested in investing in the company, please contact us.
Here you will find our quarterly newsletter, “Stratified News from Dortmund”. With our newsletter we intend to regularly update you on developments at Protagen in a fresh and colorful format and we hope that you like it.
Get in touch
Improving the treatment of cancer and autoimmune disease is our passion, and we always welcome the chance to discuss these topics with current and prospective customers, patients and clinicians alike.